Vanda Pharmaceuticals (VNDA) Total Current Liabilities (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Total Current Liabilities data on file, last reported at $135.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 30.46% year-over-year to $135.6 million; the trailing twelve-month figure through Mar 2026 stood at $135.6 million (up 30.46% YoY), and the FY2025 full-year result was $145.2 million, up 45.19% from the prior year.
• Total Current Liabilities slipped to $135.6 million in Q1 2026, from $145.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $145.2 million in Q4 2025 to a low of $84.8 million in Q3 2023.
• A 5-year average of $101.0 million and a median of $93.3 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 46.87% in 2022 and slipped 8.41% in 2023, its largest moves.
• Tracing VNDA's Total Current Liabilities over 5 years: stood at $91.4 million in 2022, then retreated by 4.09% to $87.7 million in 2023, then grew by 14.01% to $100.0 million in 2024, then surged by 45.19% to $145.2 million in 2025, then dropped by 6.6% to $135.6 million in 2026.
• Business Quant data shows VNDA's Total Current Liabilities at $135.6 million in Q1 2026, $145.2 million in Q4 2025, and $117.9 million in Q3 2025.